MedTrace Logo

Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)

NCT05746195 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-01-22

Study results available
· View outcomes & findings →

Summary

This clinical trial evaluates whether an adaptive text-message intervention is useful in helping survivors of colorectal cancers (CRC) eat more whole grain foods and less refined grain foods. Most CRC survivors don't achieve the recommended intakes of whole grains or fiber, even though there is strong evidence that a high-fiber diet rich in whole grains lowers the risk of death from CRC. Dietary interventions are a promising approach for reducing death from CRC, and text message interventions specifically are a promising tool for reaching diverse populations. This trial evaluates a text-message based dietary intervention that continuously adapts message content to be specifically tailored for the participant for increasing whole grain consumption.

Conditions

  • Colon Adenocarcinoma
  • Colorectal Carcinoma
  • Rectal Adenocarcinoma

Interventions

BEHAVIORAL

Dietary intervention via Text Messaging

Text messages will be sent to participants cell phones using the HealthySMS platform

OTHER

Survey Administration

Various questionnaires evaluating participants dietary habits and use of study intervention will be administered

BEHAVIORAL

Nutrition Education

Participants will receive nutrition education materials

Sponsors & Collaborators

Principal Investigators

  • Erin Van Blarigan, ScD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-03
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05746195 on ClinicalTrials.gov